NO971494L - Liposomformulering til behandling av virussykdommer - Google Patents

Liposomformulering til behandling av virussykdommer

Info

Publication number
NO971494L
NO971494L NO971494A NO971494A NO971494L NO 971494 L NO971494 L NO 971494L NO 971494 A NO971494 A NO 971494A NO 971494 A NO971494 A NO 971494A NO 971494 L NO971494 L NO 971494L
Authority
NO
Norway
Prior art keywords
treatment
liposomes
viral diseases
formulations
hiv
Prior art date
Application number
NO971494A
Other languages
English (en)
Norwegian (no)
Other versions
NO971494D0 (no
Inventor
Michel G Bergeron
Andre Desormeaux
Original Assignee
Michel G Bergeron
Andre Desormeaux
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Michel G Bergeron, Andre Desormeaux filed Critical Michel G Bergeron
Publication of NO971494D0 publication Critical patent/NO971494D0/no
Publication of NO971494L publication Critical patent/NO971494L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO971494A 1994-10-03 1997-04-02 Liposomformulering til behandling av virussykdommer NO971494L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31673594A 1994-10-03 1994-10-03
PCT/CA1995/000561 WO1996010399A1 (en) 1994-10-03 1995-10-03 Liposome-formulations for treatment of viral diseases

Publications (2)

Publication Number Publication Date
NO971494D0 NO971494D0 (no) 1997-04-02
NO971494L true NO971494L (no) 1997-05-27

Family

ID=23230423

Family Applications (1)

Application Number Title Priority Date Filing Date
NO971494A NO971494L (no) 1994-10-03 1997-04-02 Liposomformulering til behandling av virussykdommer

Country Status (15)

Country Link
US (1) US5773027A (de)
EP (1) EP0784470B1 (de)
JP (1) JPH10506396A (de)
CN (1) CN1165480A (de)
AT (1) ATE246920T1 (de)
AU (1) AU714043B2 (de)
BR (1) BR9509217A (de)
CA (1) CA2201631C (de)
DE (1) DE69531499T2 (de)
ES (1) ES2204964T3 (de)
MX (1) MX9702435A (de)
NO (1) NO971494L (de)
NZ (1) NZ293216A (de)
PT (1) PT784470E (de)
WO (1) WO1996010399A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7357930B1 (en) 1999-05-03 2008-04-15 Infectio Recherche Inc. Methods and formulations for targeting infectious agents bearing host cell proteins

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9605437D0 (en) * 1996-03-15 1996-05-15 Iaf Biochem Int Cytomegalovirus inhibiting compounds
US6015576A (en) * 1997-08-29 2000-01-18 Bio-Sphere Technology, Inc. Method for inducing a systemic immune response to an antigen
US6207185B1 (en) 1996-03-22 2001-03-27 Bio-Sphere Technology Method for inducing a systemic immune response to an HIV antigen
US6117449A (en) * 1996-03-22 2000-09-12 Bio-Sphere Technology, Inc. Method for inducing a systemic immune response to a hepatitis antigen
WO2003041681A2 (en) * 2001-11-13 2003-05-22 Celator Technologies, Inc. Lipid carrier compositions with enhanced blood stability
DE60222580T2 (de) * 2001-11-13 2008-06-12 Celator Pharmaceuticals, Inc. Lipidträgerzusammensetzungen und verfahren zur verbesserten wirkstoffzurückhaltung
US20130085146A1 (en) * 2003-01-14 2013-04-04 Rodney J.Y. Ho Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymphoid tissues
WO2004064731A2 (en) * 2003-01-14 2004-08-05 University Of Washington Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymlplhoid tissues
US8986731B2 (en) * 2003-08-26 2015-03-24 Biolitec Pharma Marketing Ltd Pegylated liposomal formulations of hydrophobic photosensitizers for photodynamic therapy
US20050048109A1 (en) * 2003-08-26 2005-03-03 Ceramoptec Industries, Inc. Non-polar photosensitizer formulations for photodynamic therapy
CN101588813A (zh) * 2005-04-12 2009-11-25 杜克大学 诱导人类免疫缺陷病毒的中和抗体的方法
US20110160642A1 (en) * 2007-11-15 2011-06-30 Wolfgang Neuberger Pegylated liposomal formulations for photodynamic treatment of inflammatory diseases
US9040079B2 (en) * 2007-11-19 2015-05-26 Biolitec Pharma Marketing Ltd Pegylated compounds for age-related macular degeneration
DK177532B1 (en) * 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
CA2930505C (en) 2013-12-20 2019-06-18 F. Hoffman-La Roche Ag Compounds comprising one or more hydrophobic domains and a hydrophilic domain comprising peg moieties, useful for binding cells
WO2015091953A1 (en) 2013-12-20 2015-06-25 Roche Diagnostics Gmbh Use of compounds comprising two or more hydrophobic domains and a hydrophilic domain comprising peg moieties for stabilization of a cell
JP6302560B2 (ja) 2013-12-20 2018-03-28 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリエチレングリコール部分を含む化合物を用いて支持体に細胞を固定化する方法
RU2669773C1 (ru) * 2017-05-30 2018-10-16 Федеральное государственное бюджетное учреждение "3 Центральный научно-исследовательский институт" Министерства обороны Российской Федерации Способ определения модуля скорости неманеврирующей аэродинамической цели по выборкам измерений дальности
EP4108251A1 (de) 2021-06-22 2022-12-28 Solmic Biotech GmbH Griffithsin zur verwendung in einem verfahren zur vorbeugung oder behandlung von infektionen mit respiratorischen viren
EP4306130A1 (de) 2022-07-11 2024-01-17 Solmic Biotech GmbH Inhalierbare formulierung zur verwendung bei der behandlung von bakteriellen lungeninfektionen

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4416872A (en) * 1982-03-17 1983-11-22 The United States Of America As Represented By The Secretary Of The Army Treatment of malaria with liposomes containing 8-aminoquinoline derivatives and glycoconjugates
US5254539A (en) * 1985-08-26 1993-10-19 U.S. Government, Dept. Of Health And Human Services, C/O National Institutes Of Health Method of treating HIV with 2',3'-dideoxyinosine
IL86009A (en) * 1987-04-10 1991-09-16 Us Health Liposome-encapsulated phosphorylated nucleosides for treatment of retroviral diseases
US4997761A (en) * 1987-10-06 1991-03-05 Houston Biotechnology Incorporated Phosphatidyl treatment of viral disease
ZA902710B (en) * 1989-05-22 1991-12-24 Univ Georgia Res Found Enzyme luminescence assay
US5843473A (en) * 1989-10-20 1998-12-01 Sequus Pharmaceuticals, Inc. Method of treatment of infected tissues
US5225212A (en) * 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7357930B1 (en) 1999-05-03 2008-04-15 Infectio Recherche Inc. Methods and formulations for targeting infectious agents bearing host cell proteins

Also Published As

Publication number Publication date
NZ293216A (en) 1999-03-29
EP0784470A1 (de) 1997-07-23
MX9702435A (es) 1997-06-28
CA2201631A1 (en) 1996-04-11
AU3560395A (en) 1996-04-26
DE69531499D1 (de) 2003-09-18
CN1165480A (zh) 1997-11-19
NO971494D0 (no) 1997-04-02
ES2204964T3 (es) 2004-05-01
EP0784470B1 (de) 2003-08-13
WO1996010399A1 (en) 1996-04-11
BR9509217A (pt) 1998-01-27
AU714043B2 (en) 1999-12-16
CA2201631C (en) 2004-05-04
ATE246920T1 (de) 2003-08-15
DE69531499T2 (de) 2004-06-24
US5773027A (en) 1998-06-30
JPH10506396A (ja) 1998-06-23
PT784470E (pt) 2003-12-31

Similar Documents

Publication Publication Date Title
NO971494L (no) Liposomformulering til behandling av virussykdommer
DK0774959T3 (da) Liposomalt indgivelsessystem for biologisk aktive midler
JP3240330B2 (ja) コラン酸の塩を含有する医薬調合剤および化粧品調合剤
CA2258811A1 (en) Formulation for use in the prevention of pathogen induced diseases including hiv and hsv
SE9703191L (sv) Läkemedel för förbättring av muskelfunktionsdurationen eller behandling av muskelstörningar eller -sjukdom
DE60115029D1 (de) Pharmazeutische zusammensetzungen enthaltend cannabidiol-derivate
ATE181319T1 (de) Kationische lipide für die intrazelluläre abgabe von biologisch aktiven molekülen
AU2003233921A1 (en) Atomizable liposomes and their use for the pulmonary administration of active substances
RU94036668A (ru) Средство для лечения заболеваний полости рта
WO1994027584A3 (en) Arylating medicaments
GEP20022751B (en) Aqueous Pharmaceutical Composition Comprising an Active Ingredient Which Is Highly Insoluble in Water
CA2091134A1 (en) Therapeutic agent for threatened abortion
HUP9900945A2 (hu) Nukleozidanalógok herpes simplex vírus fertőzések kombinációs terápiájában
RU98111152A (ru) Применение активного вещества флупиртина или его фармакологически приемлемых солей в качестве лекарственного средства для профилактики и лечения заболеваний, ассоциированных с повреждением клеточной системы гемопоэза
SE9900177L (sv) Användning av en beredning innehållande myrsyra för framställning av ett läkemedel för behandling av vårtor, orsakade av Papillomavirus
EP1283040A4 (de) Orale heilmittelform für dauerverabreichung
Murphy New antiretroviral drugs part I: PIs
HUP0100937A2 (hu) Többszörösen elágazó peptidkonstrukciókat tartalmazó liposzómák és alkalmazásuk humán immundeficiencia vírus ellen
DE69926633D1 (de) Injizierbare arzneiformulierungen von partricin derivaten
WO1998036778A8 (en) Sustained drug delivery and compositions useful therefor
EP0056681A3 (de) Formulierungen des Levonantradols und N-Methyllevonantradols
RU95102712A (ru) Липосомный фармацевтический препарат и лечебно-профилактический крем на его основе
Mairdan et al. Efficacy of Liposomal Albendazole for the Treatment of E. multilocularis in Rats
IT1277609B1 (it) Apparecchiatura per l'inattivazione virale di hiv in emoderivati e per supporto a trattamenti terapeutici di affezioni virali da hiv

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application